ModifiedUnitedHealthcarePolicy CS061.AB

Implanted Electrical Stimulator for the Spinal Cord

Defines UnitedHealthcare coverage stance and clinical rationale for implanted spinal cord and dorsal root ganglion stimulators for certain pain indications and identifies conditions considered unproven; applies to most UHC markets except listed state-specific policies.

Policy Summary

PayerUnitedHealthcare

PolicyImplanted Electrical Stimulator for the Spinal Cord

Policy CodePolicy CS061.AB

Change TypeTerminology and coverage clarification (material)

Effective DateFeb 1, 2026

Next Review Date

Key ActionObtain and document a successful stimulation trial and complete validated psychosocial screening, conservative management history, and required medical records for prior authorization.

SourceLink

POLICY UPDATE CHANGES

Revised list of proven and medically necessary conditions; replaced 'painful lower limb diabetic neuropathy' with 'painful diabetic neuropathy'.

Replaced language about DRG stimulation being proven and medically necessary 'in certain circumstances when performed according to FDA labeled indications' removing the qualifier referencing FDA labeled indications for some wording.

Removed reference link to the Medical Policy titled Bariatric Surgery and Gastrointestinal Motility Disorders, Diagnosis and Treatment Coverage Rationale Implanted Electrical Spinal Cord Stimulators.

Updated Clinical Evidence and References sections to reflect the most current information.

3primary proven indications listed

2unproven/not medically necessary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Implanted SCS and DRG Stimulation

Medically necessary indications (SCS)

Covered when performed according to FDA labeled indications and applicable clinical criteria (see InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion).

Proven SCS indications: Implanted electrical spinal cord stimulators are considered proven and medically necessary for complex regional pain syndrome (CRPS), painful diabetic neuropathy, and failed back surgery syndrome when performed according to U.S. Food and Drug Administration (FDA) labeled indications, contraindications, warnings, and precautions and meeting InterQual criteria.

Refer to the InterQual CP: Procedures, Spinal Cord Stimulator (SCS) Insertion for detailed clinical criteria and documentation requirements.

Medically necessary indications (DRG)

DRG stimulation covered for specific indication:

DRG indication: Dorsal root ganglion (DRG) stimulation is considered proven and medically necessary for complex regional pain syndrome (CRPS I and CRPS II) when performed according to U.S. Food and Drug Administration (FDA) labeled indications, contraindications, warnings, and precautions and meeting InterQual criteria.

Evidence base is limited; see Hayes, Nagpal et al. systematic review and InterQual guidance for supporting data.

Coverage considerations for DRG/SCS

Consider DRG or SCS when ALL of the following are met (based on trial evidence and guideline recommendations):

Patient selection and prior therapy: Chronic focal neuropathic pain (for example, CRPS, causalgia, select pelvic/groin/post‑surgical neuropathic pain) refractory to conventional medical management and conservative therapies; prior conservative treatments must have been attempted and documented.

Supported by DRG indications and systematic reviews; see InterQual for specific prior therapy duration and content.

Stimulation trial: A documented, successful stimulation trial prior to permanent implantation except where guidelines exempt trial (eg, anginal pain).Trial success often defined in literature as ≥50% pain relief.

ASRAPM recommends trial before implant; NICE also recommends successful trial for HF10 candidacy.

Psychosocial assessment: Objective validated psychosocial screening (including screening for depression) completed and documented prior to permanent implantation.

Unproven / Not medically necessary

Not medically necessary / Unproven uses (based on insufficient evidence):

Unproven SCS indications: Implanted electrical spinal cord stimulators (including DRG when not indicated) are unproven and not medically necessary for chronic intractable back pain without prior spine surgery and for refractory angina pectoris due to insufficient evidence of efficacy for these conditions.

Replacement batteries/generators for previously implanted systems are appropriate when malfunctioning and not under warranty.

HF10 (Senza) consideration

NICE recommendations for considering HF10/Senza SCS (informational):

NICE HF10 candidacy: Consider HF10 therapy (Senza) for individuals with residual chronic neuropathic back or leg pain of at least 50 mm on a 0–100 mm visual analog scale (VAS) at least six months after back surgery despite conventional medical management, AND who have had a successful stimulation trial as part of a comprehensive assessment by a multidisciplinary team.VAS >= 50 mm; duration since surgery >= 6 months

Informational: based on NICE guidance; local coverage determinations and InterQual criteria apply.

Evidence summaries (informational)

Informational evidence summaries:

Evoke SCS evidence: NICE Medtech briefing identified a small evidence base for the Evoke SCS system (one RCT and one observational study, total 184 people); experts considered Evoke likely comparable to other stimulator systems but recommended additional evidence of equivalence.

Informational only.

DRG stimulation evidence/regulatory: DRG stimulation has limited-quality evidence including RCTs (eg, ACCURATE) and systematic reviews suggesting benefit for CRPS; multiple DRG devices are available and FDA product codes are noted for regulatory reference.

Informational: see Hayes and systematic reviews for study details.

Dorsal root ganglion (DRG) stimulation is considered unproven and not medically necessary for treating conditions other than complex regional pain syndrome (CRPS) because the available evidence is insufficient to establish efficacy for other indications.

The 2022 Department of Veterans Affairs/Department of Defense (VA/DoD) Clinical Practice Guideline for low back pain specifically recommended against the use of spinal cord stimulation (SCS) for patients with routine low back pain, and this guidance should be considered when evaluating coverage for non‑neuropathic low back pain indications.

Information about U.S. Food and Drug Administration (FDA) clearance or approval of implantable spinal cord stimulation systems is provided for regulatory context, but FDA approval alone is not a basis for coverage and should not be used as the sole determinant of medical necessity.

The policy lists certain uses as unproven and not medically necessary, including chronic intractable back pain without prior spine surgery and refractory angina pectoris, reflecting insufficient evidence to support routine coverage for these indications.

Because the VA/DoD guideline recommends against SCS for nonspecific low back pain, such indications lack guideline support and should generally be excluded from coverage absent specific neuropathic diagnoses or strong supporting evidence.

The 2020 North American Spine Society (NASS) systematic review found no studies adequate to address electrical stimulation for low back pain, indicating limited or absent evidence to support SCS for this indication.

Procedure and Device Coding

CPT procedure codesCPT

63650	Percutaneous implantation of neurostimulator electrode array, epidural.
63655	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
63688	Revision or removal of implanted spinal neurostimulator pulse generator or receiver, with detachable connection to electrode array.

HCPCS supply/device codesHCPCS

L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8682	Implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.
L8695	External recharging system for battery (external) for use with implantable neurostimulator, replacement only.

FDA product codes mentionedmixed

LGW	FDA product code referenced for PMA-approved implantable SCS systems
GZB	FDA product code referenced for PMA-approved implantable SCS systems
GZF	FDA product code referenced for 510(k)-cleared SCS products
PMP	FDA product code referenced for DRG stimulation devices

Visual Analog Scale (VAS) threshold

Visual Analog Scale (VAS) thresholdVAS >= 50 mm (highlighted for candidacy assessment)

Context for thresholdUsed by NICE for considering HF10/Senza SCS candidacy (pain >=50 mm on 0–100 mm VAS)

Documentation noteRecord VAS score in multidisciplinary assessment and trial documentation

Prior Authorization, Documentation, and Provider Responsibilities

Prior Authorization

Prior Authorization and Coding References

Prior authorization is required per plan rules. Verify member benefit and obtain any required prior authorization before scheduling implantation or trial procedures. Billing and coding must follow the listed CPT and HCPCS codes; inclusion of a code in this policy is informational and does not guarantee payment.

Verify benefit eligibility and prior authorization requirements per the member's federal/state/contractual plan before service
Reference CPT: 63650, 63655, 63685, 63688
Reference HCPCS: L8679, L8680, L8682, L8685, L8686, L8687, L8688, L8695

Prior Authorization

Prior Authorization: Trial and Assessment

Prior authorization requests must confirm that a stimulation trial was performed (unless anginal pain) and that a validated psychosocial screening was completed as part of a multidisciplinary assessment. Documentation of the trial response and multidisciplinary evaluation is required to evaluate medical necessity.

Confirm SCS trial completed prior to permanent implantation except when treating anginal pain

Conservative Management and Trial Requirements

Attempt and document appropriate conservative management prior to trial/stimulation

Attempt and document appropriate conservative management prior to trial/stimulation:

Document prior conservative treatments: Documented attempts at conventional medical management and conservative therapies (eg, medications, physical therapy, TENS, injections) prior to considering a stimulation trial; details of treatments and durations should be available for review.

InterQual CP provides explicit prior therapy requirements; documentation is required for prior authorization and medical necessity review.

Timeframe and response: Documentation should include timing and response to prior therapies and rationale for progressing to trial stimulation (eg, persistent focal neuropathic pain despite adequate trials of conservative care).

Supported by systematic reviews and clinical trials informing selection criteria.

Documented failure of CMM

Documented failure of conventional medical management (CMM):

Imaging and Clinical Assessment Requirements

Documentation Required

Provide ischemia-proving study (e.g., MIBI-SPECT) for refractory angina workup

For refractory angina pectoris workup, expect ischemia confirmation by studies such as MIBI-SPECT when clinically appropriate; include imaging results if available.

Provide MIBI-SPECT or equivalent ischemia-proving study results when applicable to the angina evaluation.
Document CCS class and angina severity measures if available.

Documentation Required

Perform and document multidisciplinary assessment including VAS

Assess candidates with a multidisciplinary evaluation including pain severity assessment (e.g., VAS) and tailored testing as needed; document the multidisciplinary assessment in the record.

Include multidisciplinary team members' evaluations and objective pain scores in the authorization record.
Tailor additional testing to the clinical presentation and document rationale.

Non-covered / Not Medically Necessary Indications

UnitedHealthcare does not cover certain uses: chronic intractable back pain without prior spine surgery is listed as unproven and not medically necessary, and refractory angina pectoris is likewise listed as unproven in the policy and therefore not covered in routine circumstances.

This block duplicates other not‑covered statements in the policy listing chronic intractable back pain without prior spine surgery and refractory angina pectoris as unproven and not medically necessary, preserved here for reconciliation with source documentation.

This block repeats the policy's not‑covered entries for continuity with source text: implanted SCS for chronic intractable back pain without prior spine surgery and for refractory angina pectoris are described as unproven and not medically necessary.

The NASS 2020 evidence review concluded there were no adequately designed studies addressing electrical stimulation for low back pain, supporting the policy position that SCS/electrical stimulation lacks sufficient evidence for routine use in low back pain.

Definitions and Key Evidence Terms

Proven (medically necessary) indications

Complex regional pain syndrome (CRPS)Proven and medically necessary for implanted SCS and for DRG stimulation (CRPS I and II) in certain circumstances

Painful diabetic neuropathyListed as a proven and medically necessary indication for implanted electrical spinal cord stimulators

Failed back surgery syndromeProven and medically necessary for implanted electrical spinal cord stimulators when criteria met

Unproven / not medically necessary indications

Chronic intractable back pain without prior spine surgeryConsidered unproven and not medically necessary due to insufficient evidence

Refractory angina pectorisListed as unproven and not medically necessary for implanted SCS (insufficient evidence)

Frequency and Utilization Limits

Frequency limits (not specified)

Frequency limit statementNo explicit frequency limits provided in this document excerpt.

Action for providersRefer to plan-specific benefits and InterQual criteria for any frequency-related authorization rules

Documentation noteIf frequency limits are required for adjudication, request supporting plan language or benefit schedule

Background and Context

Spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation are implantable neuromodulation therapies used to treat certain chronic neuropathic and postsurgical pain syndromes. The policy recognizes DRG stimulation as proven and medically necessary for CRPS I and II in certain circumstances, notes SCS is proven for indications such as CRPS, painful diabetic neuropathy, and failed back surgery syndrome when criteria are met, and emphasizes trial stimulation, multidisciplinary assessment, and documentation per referenced clinical guidance.

Policy Summary

PayerUnitedHealthcare

PolicyImplanted Electrical Stimulator for the Spinal Cord

Policy CodePolicy CS061.AB

Change TypeTerminology and coverage clarification (material)

Effective DateFeb 1, 2026

Next Review Date

Key ActionObtain and document a successful stimulation trial and complete validated psychosocial screening, conservative management history, and required medical records for prior authorization.

SourceLink

On This Page

Documentation Required

Medical Records Documentation

Medical records may be required to assess whether the member meets clinical criteria. Absence of required documentation may result in denial or inability to verify medical necessity; benefit coverage is determined by the member's plan contract and applicable laws.

Provide complete medical records to support the request; incomplete records can delay or result in denial
Benefit coverage is subject to federal, state, or contractual requirements and applicable laws

Documentation Required

Trial Stimulation Recommendation

Guideline consensus recommends performing an SCS trial prior to permanent implantation except for anginal pain. Failure to perform a trial (when indicated) may be considered inconsistent with guideline-based practice and could affect coverage decisions.

Document why a trial was not performed when a permanent implant is requested (only acceptable exception: anginal pain)
Trial results should show sufficient pain reduction to support proceeding to permanent implantation

Documentation Required

Medical Records for Review

Medical records requested for review should include detailed trial and multidisciplinary assessment documentation. Lack of required elements may prevent verification of clinical criteria and result in denial.

Include trial stimulation report, multidisciplinary team notes, and psychosocial screening results
Include prior treatment history and documentation of conservative management attempts

Documentation Required

Required Documentation Elements

Required documentation elements for prior authorization and medical review consist of specific clinical and procedural items. Submit all elements to allow timely determination of medical necessity.

Stimulation trial details: type of trial (percutaneous/temporary), duration, and quantitative response (e.g., % pain reduction)
Validated psychosocial screening results (e.g., depression screen) and assessment by multidisciplinary team
Indication specifics: diagnosis (CRPS, diabetic neuropathy, failed back surgery syndrome), symptom duration, and prior conservative therapies tried

Documentation Required

Trial and Multidisciplinary Assessment Documentation

Document trial and multidisciplinary assessment elements that support a permanent implant: failed back surgery status (when applicable), baseline pain severity (e.g., VAS >= 50 mm or equivalent), duration since surgery, and evidence of a successful trial response. These items are used to evaluate treatment sequencing and adherence to guideline-based selection.

If post-surgical: document failed back surgery syndrome, time since last surgery, and prior treatments
Baseline pain severity (document VAS or NRS) — e.g., >= 50 mm VAS when applicable
Successful trial response documented (e.g., >= 50% pain reduction) with objective measures and patient-reported outcomes

Step Therapy

Evidence-Based Treatment Sequencing

Evidence supports sequencing SCS in context of guideline recommendations and comparative trials: randomized trials of SCS plus conventional medical management (CMM) vs CMM alone have shown greater responder rates for SCS in certain populations (including nonsurgical refractory back pain and 10-kHz SCS studies). However, some guidelines (VA/DoD) recommend against SCS for low back pain; coverage decisions should consider the evidence, guideline guidance, and patient-specific factors.

Trials show SCS + CMM often yields higher responder rates than CMM alone in selected populations (e.g., NSRBP, 10-kHz SCS)
Consider guideline recommendations and device-specific indications when sequencing care; VA/DoD guidance advises against SCS for low back pain
Ensure conservative management has been attempted per guidelines (NICE/ASRAPM) before SCS in applicable cases

Prior Authorization

Conservative Management and Trial Requirement

Conservative management and trial requirement: consistent with NICE and ASRAPM guidance, patients should have appropriate conservative management and a prior stimulation trial as part of a multidisciplinary assessment before permanent implantation for HF10/SCS and similar therapies.

Document attempts at conservative care (medication optimization, physical therapy, other noninvasive modalities) prior to SCS consideration
For HF10/SCS, ensure at least six months since back surgery (when applicable) and a successful stimulation trial as noted by NICE

Documentation Required

Include stimulation trial within comprehensive multidisciplinary evaluation; adapt as needed

Stimulation trials and assessments should be performed as part of a comprehensive multidisciplinary evaluation; adapt testing and assessment methods for patients with disabilities or communication difficulties.

Document how assessments or trial methods were adapted for physical, sensory, linguistic, or communication limitations.
Ensure trial results are evaluated and recorded by the multidisciplinary team.